Power your medicine
With its product NBTXR3, Nanobiotix is currently running trials in several indications across Europe, the USA and the Asia-Pacific Region: a registration trial in Soft Tissue Sarcoma, and Phase I/II trials in Liver cancers (HCC and Metastatic), Head and Neck cancers, Prostate cancer and in Asia via its partner PharmaEngine, Rectal cancer and Head and Neck cancers treated by radiotherapy plus chemotherapy.
NBTXR3 – Prostate cancer – Phase I/II
A Phase I-II Dose Escalation Study of NBTXR3 Activated by External Beam Radiation Therapy or External Beam Radiotherapy with Brachytherapy in Subjects with Newly Diagnosed Unfavorable Intermediate Risk or High Risk Prostate Adenocarcinoma Treated with Androgen Deprivation
clinicaltrials.gov | Phase I/II | USA | Recruiting
NBTXR3 – Head and Neck cancer – Phase I/II – Sponsored by PharmaEngine
A Study of NBTXR3 (PEP503) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
clinicaltrials.gov | Phase I/II | Asia-Pacific | Recruiting